Common Genetic Variant Risk Score Is Associated With Drug-Induced QT Prolongation and Torsade de Pointes Risk | Zendy

David G. Strauss | Zendy; José Vicente | Zendy; Lars Johannesen | Zendy; Ksenia Blinova | Zendy; Jay W. Mason | Zendy; Peter Weeke | Zendy; Elijah R. Behr | Zendy; Dan M. Roden | Zendy; Raymond L. Woosley | Zendy; Gülüm Kosova | Zendy; Michael A. Rosenberg | Zendy; Christopher NewtonCheh | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Common Genetic Variant Risk Score Is Associated With Drug-Induced QT Prolongation and Torsade de Pointes Risk

Author(s) -

David G. Strauss,

José Vicente,

Lars Johannesen,

Ksenia Blinova,

Jay W. Mason,

Peter Weeke,

Elijah R. Behr,

Dan M. Roden,

Raymond L. Woosley,

Gülüm Kosova,

Michael A. Rosenberg,

Christopher NewtonCheh

Publication year - 2017

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.116.023980

Subject(s) - medicine , prolongation , qt interval , long qt syndrome , torsades de pointes , drug , cardiology , pharmacology

Drug-induced QT interval prolongation, a risk factor for life-threatening ventricular arrhythmias, is a potential side effect of many marketed and withdrawn medications. The contribution of common genetic variants previously associated with baseline QT interval to drug-induced QT prolongation and arrhythmias is not known.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research